Tebentafusp shows sustained benefit only in a small proportion of patients with metastatic uveal melanoma
Novel targeted strategies are investigated in uveal melanoma, especially for those who do not respond to the bispecific fusion protein, with some encouraging early-phase data from c-MET/PKC inhibitors
Induction chemotherapy before CRT improves outcomes in locally advanced cervical cancer
Phase III trial findings reveal significant improvements in PFS and OS rates, although the population studied may not be wholly indicative of high-risk disease
Combination therapies with immunotherapy and ADCs prolong overall survival in urothelial carcinoma
Positive outcomes in advanced or metastatic disease reported from EV-302/KEYNOTE-A39 and CheckMate 901 indicate an alternative to first-line chemotherapy for the first time
Neoadjuvant nivolumab plus relatlimab shows benefit in MMR-deficient colon cancers
In the NICHE-3 study, all patients achieved a pathological response
Advanced pancreatic cancer: is triple chemotherapy into question?
Results presented at ESMO Congress 2023 open-up an interesting debate on the use of currently recommended treatment regimens
Triplet therapy does not outperform doublet treatment first line in metastatic pancreatic cancer
Results from the JCOG1611-GENERATE trial fuel the debate around the preferred option in this setting
New treatment paradigms may offer advances in pancreatic cancer treatments
Neoadjuvant, perioperative, targeted and combined treatment approaches have shown potential benefit for patients with this aggressive disease, but further research is needed
Early-phase trials demonstrate new frontiers for ADCs in breast cancer
Encouraging preliminary results are reported with innovative antibody–drug conjugate designs, but underlying mechanisms of action still need to be described to improve efficacy and tolerability
Single-agent milademetan fails to improve outcomes in dedifferentiated liposarcomas
Disappointing results were reported from the phase III MANTRA trial, but biomarker-based approaches still offer hope for MDM2 inhibition in solid tumours
Novel immunotherapy-based treatment strategies offer benefits to patients with sarcoma
Results from four early-phase studies show that combining immune checkpoint inhibitors with other immunotherapies or with TKIs is a potentially efficacious strategy for the treatment of different diseases including GIST and vascular sarcomas